Drugs / HDM2005
Trials 4 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT07697339 | Jul 2026 → Aug 2027 expected | mantle cell lymphoma | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07004296 | May 2025 → Jul 2027 expected | cancer | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT06615193 | Aug 2024 → Jun 2026 overdue | cancer, lymphoma | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT07124936 | Jul 2025 → Oct 2027 expected | diffuse large B-cell lymphoma | Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HDM2005 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07697339 ↗ |
| Route | Intravenous | “HDM2005 will be administered via IV infusion.” NCT06615193 ↗ |